AU537093B2 - New imidazo-rifamycin derivatives with antibacterial utility - Google Patents

New imidazo-rifamycin derivatives with antibacterial utility

Info

Publication number
AU537093B2
AU537093B2 AU70655/81A AU7065581A AU537093B2 AU 537093 B2 AU537093 B2 AU 537093B2 AU 70655/81 A AU70655/81 A AU 70655/81A AU 7065581 A AU7065581 A AU 7065581A AU 537093 B2 AU537093 B2 AU 537093B2
Authority
AU
Australia
Prior art keywords
rifamycin derivatives
new imidazo
antibacterial utility
antibacterial
utility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU70655/81A
Other languages
English (en)
Other versions
AU7065581A (en
Inventor
Egidio Marchi
Lauretta Montecchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Farmaceutici SpA
Original Assignee
Alfa Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici SpA filed Critical Alfa Farmaceutici SpA
Publication of AU7065581A publication Critical patent/AU7065581A/en
Application granted granted Critical
Publication of AU537093B2 publication Critical patent/AU537093B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU70655/81A 1980-05-22 1981-05-18 New imidazo-rifamycin derivatives with antibacterial utility Expired AU537093B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT03429/80A IT1154655B (it) 1980-05-22 1980-05-22 Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT342980 1980-05-22

Publications (2)

Publication Number Publication Date
AU7065581A AU7065581A (en) 1981-11-26
AU537093B2 true AU537093B2 (en) 1984-06-07

Family

ID=11107198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70655/81A Expired AU537093B2 (en) 1980-05-22 1981-05-18 New imidazo-rifamycin derivatives with antibacterial utility

Country Status (25)

Country Link
US (1) US4341785A (enExample)
JP (1) JPS5711987A (enExample)
AR (1) AR226212A1 (enExample)
AT (1) AT373599B (enExample)
AU (1) AU537093B2 (enExample)
BE (1) BE888895A (enExample)
CA (1) CA1142518A (enExample)
CH (1) CH648037A5 (enExample)
DE (1) DE3120460A1 (enExample)
DK (1) DK157876C (enExample)
EG (1) EG14891A (enExample)
ES (1) ES8203388A1 (enExample)
FI (1) FI69467C (enExample)
FR (1) FR2482967A1 (enExample)
GB (1) GB2079270B (enExample)
GR (1) GR75640B (enExample)
IE (1) IE51204B1 (enExample)
IT (1) IT1154655B (enExample)
LU (1) LU83376A1 (enExample)
NL (1) NL187022C (enExample)
NO (1) NO155622C (enExample)
PH (2) PH17207A (enExample)
PT (1) PT73064B (enExample)
SE (1) SE453089B (enExample)
ZA (1) ZA813430B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
EP0861660B9 (en) * 1997-02-28 2006-06-28 Kaneka Corporation Curative medicine for disease caused by infection of Helicobacter
WO2003045319A2 (en) * 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
WO2003051299A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
EP1560566B1 (en) * 2002-11-05 2012-04-11 Fadim S.r.l. Controlled and continued delivery of rifaximin
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7265107B2 (en) * 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7256187B2 (en) * 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7202246B2 (en) * 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN101282981B (zh) 2005-08-11 2012-09-26 塔甘塔治疗公司 膦酸化利福霉素及其在预防和治疗骨和关节感染中的用途
CA2643364C (en) 2006-03-09 2017-06-06 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
ES2538478T3 (es) 2006-08-02 2015-06-22 Salix Pharmaceuticals, Inc. Métodos para el tratamiento de enteritis por radiación
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101480732B1 (ko) * 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
EP3714878B1 (en) 2007-07-06 2022-01-19 Lupin Limited Pharmaceutical compositions of rifaximin
US8383151B2 (en) 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG10201607926VA (en) * 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
ES2727728T3 (es) 2008-02-26 2019-10-18 Salix Pharmaceuticals Ltd Métodos para el tratamiento del síndrome del intestino irritable
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
WO2010019511A2 (en) 2008-08-13 2010-02-18 Targanta Therapeutics Corp. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
EP2350096B1 (en) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CA2745980C (en) 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP2437603A4 (en) 2009-06-02 2012-12-12 Salix Pharmaceuticals Ltd METHODS OF TREATING HEPATIC ENCEPHALOPATHY
CA2773982C (en) 2009-09-13 2018-12-04 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
PE20121185A1 (es) 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd METHOD FOR THE TREATMENT OF INFECTIONS
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) 2010-03-10 2017-03-08 ルピン・リミテッドLupin Limited リファキシミン使用準備済懸濁液
EP3750526A1 (en) 2010-07-12 2020-12-16 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
AU2012214239B2 (en) 2011-02-11 2016-06-30 Salix Pharmaceuticals, Ltd. Forms of Rifaximin and uses thereof
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
RU2496475C2 (ru) 2011-10-26 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция и набор для лечения бактериальных инфекций
ES2986825T3 (es) 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
EP2807148A4 (en) * 2012-01-25 2015-04-08 Salix Pharmaceuticals Ltd RIFAXIMIN DERIVATIVE AND USES THEREOF
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニAlfa Wassermann S.P.A. 膣感染症を診断するための方法
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN110770244A (zh) * 2017-06-26 2020-02-07 倍尔福股份公司 吡啶并咪唑利福霉素衍生物的抗菌剂
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273377C (enExample) *
AT273377B (de) * 1967-03-01 1969-08-11 Lepetit Spa Verfahren zur Herstellung von neuen Rifamycinen
AT344898B (de) * 1975-06-13 1978-08-10 Archifar Ind Chim Trentino Verfahren zur herstellung neuer rifamycin-verbindungen
DK345977A (da) * 1976-09-30 1978-03-31 Archifar Ind Chim Trentino G rifamycinforbindelser og fremgangsmaade til deres fremstillin
CH629212A5 (it) * 1976-10-18 1982-04-15 Erba Farmitalia Procedimento per la preparazione di composti di rifamicina.
CH633014A5 (en) * 1978-06-09 1982-11-15 Erba Farmitalia Rifamycin compounds

Also Published As

Publication number Publication date
PH18704A (en) 1985-09-05
NL187022C (nl) 1991-05-01
SE453089B (sv) 1988-01-11
IT1154655B (it) 1987-01-21
ES502906A0 (es) 1982-04-01
JPS5711987A (en) 1982-01-21
GB2079270A (en) 1982-01-20
NO155622B (no) 1987-01-19
IE51204B1 (en) 1986-10-29
ES8203388A1 (es) 1982-04-01
US4341785A (en) 1982-07-27
DE3120460A1 (de) 1982-03-11
IE811139L (en) 1981-11-22
AU7065581A (en) 1981-11-26
NO155622C (no) 1987-04-29
JPS6123192B2 (enExample) 1986-06-04
BE888895A (fr) 1981-09-16
EG14891A (en) 1985-12-31
CA1142518A (en) 1983-03-08
NL8102290A (nl) 1981-12-16
NL187022B (nl) 1990-12-03
GR75640B (enExample) 1984-08-02
PT73064B (en) 1982-07-05
SE8103216L (sv) 1981-11-23
FI811565L (fi) 1981-11-23
GB2079270B (en) 1984-01-18
AT373599B (de) 1984-02-10
NO811731L (no) 1981-11-23
DK157876C (da) 1990-07-30
DK224781A (da) 1981-11-23
ATA222781A (de) 1983-06-15
FI69467B (fi) 1985-10-31
CH648037A5 (de) 1985-02-28
DK157876B (da) 1990-02-26
FR2482967B1 (enExample) 1985-03-29
DE3120460C2 (enExample) 1990-12-13
AR226212A1 (es) 1982-06-15
LU83376A1 (fr) 1981-09-11
FR2482967A1 (fr) 1981-11-27
PT73064A (en) 1981-06-01
IT8003429A0 (it) 1980-05-22
ZA813430B (en) 1982-06-30
PH17207A (en) 1984-06-19
FI69467C (fi) 1986-02-10

Similar Documents

Publication Publication Date Title
AU537093B2 (en) New imidazo-rifamycin derivatives with antibacterial utility
AU534981B2 (en) Prefabricated utility block
AU542623B2 (en) 1-hydroxyethyl-azole derivatives
AU557689B2 (en) 1-sulfo-2-oxoazetidine derivatives
AU544723B2 (en) Imidazolylpropanol derivatives
AU7259181A (en) 17-disubstituted-androst-4-en-3-one derivatives
AU522042B2 (en) Alpha-aminobenzylpencillin derivatives with antibacterial activity
AU534878B2 (en) Amino-saccharide derivatives
AU536144B2 (en) Nitrothiophene derivatives
AU544527B2 (en) Bis-carboxamide derivatives
AU554360B2 (en) S-triazinyl-aminofluorescein derivatives
AU545357B2 (en) Triazolo-benzodiazepine derivatives
AU524823B2 (en) Thiophene derivatives
AU6030380A (en) New carboxylates
AU544907B2 (en) Isonicotinanilide derivatives
AU540239B2 (en) 2-guanidinothiazole derivatives
AU547727B2 (en) Antibacterial benzylpyrimidines
AU539443B2 (en) Phenoxybutyltriazole derivatives
AU537942B2 (en) Substituted thiophine derivatives
AU526593B2 (en) Tetrahydropyranyl derivatives with antibacterial property
AU6898281A (en) Biphenylyl-azolylethane derivatives
AU7486481A (en) N-oxyamide derivatives
AU7494381A (en) Fluorinated-1-azolyl-butane derivatives
AU7705781A (en) Pyrazole-substituted oximino-cyano-acetamide derivatives
AU541157B2 (en) Pyridinethiolato-aluminium derivatives

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired